Observational studyPloS one2022

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.

Ekaterina A Bryushkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.